natgillin/translations-raw huggingface dataset:
Mild renal tubular degeneration was confined to mice exposed with at least twice the recommended human exposure; the kidney was unaffected in rats and dogs. 
Blaga degeneracija ledvičnih tubulov je bila omejena na miši, izpostavljene najmanj dvakratni priporočeni ekspoziciji pri ljudeh; pri podganah in psih ledvice niso bile prizadete.
• medicines that cause a reaction with alcohol (e.g. disulfiram). 
- zdravila, ki povzročijo reakcijo z alkoholom (npr. disulfiram).
How should I store Kaletra and for how long? 
Kako naj shranjujem zdravilo Kaletra in koliko časa
If you are taking Kaletra once a day 
Če jemljete zdravilo Kaletra enkrat na dan
How should I dispose of any unused Kaletra? 
Kako naj zavržem neporabljeno zdravilo Kaletra
• Kaletra does not reduce the risk of passing HIV to others. 
- Zdravilo Kaletra ne zmanjša tveganja za prenos HIV na druge.
- 1% (95% CI: -10, 18) (n=6) 
- 1 % (95 % IZ: -10, 18) (n=6)
The efficacy data favouring the twice-daily regimen are reinforced by a differential in pharmacokinetic parameters significantly favouring the twice-daily regimen (see section 5.2). 
Podatki o učinkovitosti, ki kažejo v prid odmerjanju dvakrat na dan, so še dodatno podprti z razliko v farmakokinetičnih parametrih, ki signifikantno podpirajo režim jemanja dvakrat na dan (glejte poglavje 5.2).
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. 
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V*.
Virologic failure* *Defined as confirmed plasma HIV-1 RNA level > 400 copies/ml at 24 weeks or viral rebound > 4000 copies/ml after Week 24. 
Virološki neuspeh* *Definiran kot potrjena raven HIV-1 RNA v plazmi > 400 kopij/ml v 24. tednu ali virološki preobrat > 4000 kopij/ml po 24. tednu.
As a general rule, when deciding to use antiretroviral agents for the treatment of HIV infection in pregnant women and consequently for reducing the risk of HIV vertical transmission to the newborn, the animal data as well as the clinical experience in pregnant women should be taken into account in order to characterise the safety for the foetus. 
V splošnem je pri odločanju uporabe protiretrovirusnega zdravila za zdravljenje infekcije z virusom HIV pri nosečnicah in posledično za zmanjšanje tveganja vertikalnega prenosa virusa HIV na novorojenčka potrebno upoštevati tako podatke na živalih kot klinične izkušnje pri nosečnicah, da se oceni varnost za fetus.
In addition, they contained a median of 3 mutations at amino acid positions 20, 24, 46, 53, 71 and 90. 
Poleg tega so imeli mediano 3 mutacije na aminokislinskih položajih 20, 24, 46, 53, 71 in 90.
Post-marketing cases have been reported indicating a potential interaction between ritonavir containing products and levothyroxine. 
V obdobju trženja so poročali o primerih, ki kažejo na potencialno interakcijo med zdravili, ki vsebujejo ritonavir in levotiroksin.
Outcomes at Week 24: Study P1030 Age: ≥ 14 days and < 6 weeks (N=10) 
Rezultati v 24. tednu: Študija P1030 Starost: ≥ 14 dni in < 6 tednov (N=10)
Kaletra oral solution is available for patients who cannot take tablets. 
Zdravilo Kaletra peroralna raztopina je na voljo za bolnike, ki ne morejo zaužiti tablet.
Decreased exposure of Kaletra may result in potential loss of virological response. 
Zmanjšana izpostavljenost zdravilu Kaletra lahko vodi v potencialno izgubo virološkega odziva.
The CHER study was a randomized, open-label study comparing 3 treatment strategies (deferred treatment, early treatment for 40 weeks, or early treatment for 96 weeks) in children with perinatally acquired HIV-1 infection. 
Študija CHER je bila randomizirana, odprta študija, v kateri so primerjali 3 strategije zdravljenja (odloženo zdravljenje, zgodnje 40-tedensko zdravljenje ali zgodnje 96-tedensko zdravljenje) pri otrocih s perinatalno okužbo s HIV-1.
• Once-daily administration of lopinavir/ritonavir is not recommended for pregnant women due to the lack of pharmacokinetic and clinical data. 
• Uporaba lopinavirja/ritonavirja enkrat na dan ni priporočljiva za nosečnice zaradi pomanjkanja farmakokinetičnih in kliničnih podatkov.
In vitro selection of resistance 
Odpornost In vitro selekcija odpornosti
Kaletra should be prescribed by physicians who are experienced in the treatment of HIV infection. 
Zdravilo Kaletra morajo predpisovati zdravniki, ki imajo izkušnje z zdravljenjem okužbe s HIV.
Concomitant administration of these medicinal products is not recommended. 
Sočasna uporaba teh zdravil ni priporočljiva.
Lack of resistance to lopinavir was confirmed by phenotypic analysis. 
Odsotnost odpornosti proti lopinavirju je bila potrjena s fenotipskimi analizami.
• yellowing of the skin or whites of eyes (jaundice); 
• porumenitev kože ali beločnic (zlatenica);
They may modify or increase the effect of other medicines. 
Spremenijo ali zvečajo lahko učinke drugih zdravil.
When Kaletra is administered concomitantly with bosentan, the efficacy of the HIV therapy should be monitored and patients should be closely observed for bosentan toxicity, especially during the first week of co-administration. 
Če je zdravilo Kaletra uporabljeno sočasno z bosentanom, je treba učinkovitost zdravljenja HIV kontrolirati, bolnike pa skrbno opazovati glede toksičnosti bosentana, zlasti prvi teden sočasne uporabe.
In case of concomitant antiviral therapy for hepatitis B or C, please refer to the relevant product information for these medicinal products. 
V primeru sočasnega protivirusnega zdravljenja proti hepatitisu B in C je treba upoštevati tudi ustrezne informacije o teh zdravilih.
It belongs to a group of medicines called protease inhibitors. 
Spada v skupino, ki jo imenujemo zaviralci proteaz.
• plaque building up inside your arteries which could lead to heart attack and stroke; 
- nastajanje plakov v vaših arterijah, ki bi lahko vodili do srčnega infarkta in možganske kapi;
It may modify or increase the effects of other medicines. 
Spremeni ali zveča lahko učinke drugih zdravil.
Of these, isolates from 96 nelfinavir-treated patients and 51 lopinavir/ritonavir-treated patients could be amplified for resistance testing. 
Od teh bi bili lahko izolati od 96 bolnikov, zdravljenih z nelfinavirjem, in od 51 bolnikov, zdravljenih z lopinavirjem/ritonavirjem, razširjeni v testiranje odpornosti.
Fluvastatin is partially metabolised by CYP2C9. 
Presnova fluvastatina delno poteka s CYP2C9.
Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu 
Podrobnejše informacije o zdravilu so na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu
Paediatric population aged from 14 days and older The oral solution formulation is the recommended option for the most accurate dosing in children based on body surface area or body weight. 
Pediatrična populacija, stari 14 dni in več Formulacija v obliki peroralne raztopine je priporočena možnost za najnatančnejše odmerjanje pri otrocih na podlagi telesne površine ali telesne mase.
In most of these cases patients have had a prior history of pancreatitis and/or concurrent therapy with other medicinal products associated with pancreatitis. 
Večinoma so imeli ti bolniki anamnezo pankreatitisa in/ali hkratnega zdravljenja z drugimi zdravili, povezanimi s pankreatitisom.
Hepatic changes indicated cellular swelling with focal degeneration. 
Spremembe na jetrih so pokazale celično nabreklost s fokalno degeneracijo.
For adults and children weighing greater than 15 kg. 
Za odrasle in otroke, ki tehtajo več kot 15 kg.
To enhance bioavailability and minimise variability Kaletra is to be taken with food. 
Za izboljšanje biološke uporabnosti in zmanjšanje variabilnosti je zdravilo Kaletra treba jemati s hrano.
While exposure eliciting these changes were comparable to or below human clinical exposure, dosages in animals were over 6-fold the recommended clinical dose. 
Čeprav je bila izpostavljenost, ki je izzvala te spremembe, primerljiva klinični izpostavljenosti pri ljudeh ali manjša od nje, so odmerki pri živalih več kot 6-krat presegali priporočeni klinični odmerek.
Antibiotics Clarithromycin 
Antibiotiki Klaritromicin
Rinse the syringe and plunger with clean water. 
Brizgo in bat splaknite s čisto vodo.
This may be unsuitable in hereditary fructose intolerance. 
To utegne biti neprimerno v primeru podedovane intolerance za fruktozo.
The safety and efficacy of Kaletra has not been established in patients with significant underlying liver disorders. 
Varnost in učinkovitost zdravila Kaletra nista ugotovljeni pri bolnikih s pomembnimi osnovnimi boleznimi jeter.
If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment. 
Če opazite kakršnekoli simptome infekcij ali druge simptome, kot so mišična šibkost, šibkost, ki se začenja v dlaneh in stopalih ter se premika proti trupu, močno bitje srca, tresavica ali hiperaktivnost, takoj obvestite zdravnika, da vam določi primerno zdravljenje.
Co-administration is contraindicated. 
Sočasna uporaba je kontraindicirana.
In some cases the hepatic dysfunction was serious. 
V nekaterih primerih je prišlo do resne disfunkcije jeter.
In general, rebound isolates either retained (if cross-resistant at baseline) or developed significant cross-resistance to indinavir, saquinavir and atazanavir. 
Na splošno so izolati po preobratu ohranili (če je bila navzkrižna odpornost prisotna izhodiščno) ali razvili pomembno navzkrižno odpornost proti indinavirju, sakvinavirju in atazanavirju.
HIV CCR5 - antagonist Maraviroc 
Zaviralci HIV CCR5 Maravirok
Among 13 subjects with viral failure in the lopinavir/ritonavir group with resistance data available no resistance to lopinavir/ritonavir was found. 
Med 13 preiskovanci z virološkim neuspehom v skupini lopinavir/ritonavir med razpoložljivimi podatki o odpornosti niso ugotovili odpornosti na lopinavir/ritonavir.
The adequate dosing may be achieved with the two available strengths of Kaletra tablets: 100/25 mg and 200/50 mg.* 
Zadostne odmerke se lahko doseže z dvema dosegljivima jakostima zdravila Kaletra tablet: 100/25 mg in 200/50 mg.*
3 tablets (300/75 mg) 4 tablets (400/100 mg) *weight based dosing recommendations are based on limited data 
3 tablete (300/75 mg) 4 tablete (400/100 mg) *smernice za odmerjanje glede na telesno maso temeljijo na omejenih podatkih
Genotypic and phenotypic analysis of viruses selected in these passages suggest that the presence of ritonavir, at these concentration ratios, does not measurably influence the selection of lopinavir-resistant viruses. 
Genotipska in fenotipska analiza virusov, selekcioniranih med temi prehodi, nakazuje, da prisotnost ritonavirja v teh koncentracijskih razmerjih nima merljivega vpliva na selekcijo virusov, odpornih proti lopinavirju.
Pull up the plunger until the correct dose amount is shown on the plunger. 
Bat vlecite navzgor, dokler se na batu ne pokaže pravi odmerek.
Dose adjustment has not been evaluated in clinical practice 
Prilagoditev odmerka ni ovrednotena v klinični praksi
Do not use the dosing syringes supplied with Kaletra oral solution to administer any other medicines you or your child may be taking. 
Brizg za peroralno dajanje , ki so priložene k zdravilu Kaletra, ne uporabljajte za dajanje nobenega drugega zdravila, ki bi ga lahko jemali vi ali vaš otrok.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please inform your doctor or pharmacist. 
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
NC= Failure 
NC = neuspeh Ugotovljeni podatki
Age: ≥ 6 weeks and < 6 months (N=21) 
Starost: ≥ 6 tednov in < 6 mesecev (N=21)
Lamotrigine and Valproate 
Lamotrigin in valproat
Inhibition of HIV protease prevents cleavage of the gag-pol polyprotein resulting in the production of immature, non-infectious virus. 
Zavrtje proteaze HIV prepreči razcep poliproteina gag-pol, tako da nastane nezrel, neinfektivni virus.
• In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. 
- Pri bolnikih z napredovano HIV infekcijo in z zgodovino opurtunistične infekcije se lahko znaki in simptomi vnetja prejšnje infekcije pojavijo kmalu po uvedbi zdravljenja virusa HIV.
Erectile dysfunction medicines (avanafil, vardenafil, sildenafil, tadalafil) 
Zdravila za zdravljenje erektilne disfunkcije (avanafil, vardenafil, sildenafil, tadalafil)
Other side effects that have been reported with Kaletra: 
Drugi neželeni učinki, o katerih so poročali pri zdravilu Kaletra:
• impotence, abnormally heavy or extended menstrual flow or a lack of menstruation; 
- impotenca, nenormalno močna ali podaljšana menstrualna krvavitev ali odsotnost menstruacije;
Given the pharmacokinetic interaction between Kaletra and tenofovir (see section 4.5), the results of this study might not be strictly extrapolable when other backbone regimens are used with Kaletra. 
Glede na farmakokinetične interakcije med zdravilom Kaletra in tenofovirjem (glejte poglavje 4.5) rezultatov te študije morda ni mogoče strogo ekstrapolirati na uporabo zdravila Kaletra z drugimi osnovnimi shemami.
Fournier Laboratories Ireland Limited, Carrigtwohill Business Park, Anngrove, Carrigtwohill, Co. Cork, Ireland 
Fournier Laboratories Ireland Limited, Carrigtwohill Business Park, Anngrove, Carrigtwohill, Co. Cork, Irska
• damage to nerves of the peripheral nervous system; 
- poškodbe perifernih živcev;
EU/1/01/172/005 - multipack: 120 (3 packs of 40) film-coated tablets EU/1/01/172/008 - carton of 120 film-coated tablets 
EU/1/01/172/005 - multipakiranje: 120 (3 škatle po 40) filmsko obloženih tablet EU/1/01/172/008 - škatla s 120 filmsko obloženimi tabletami
Use in adults 
Uporaba pri odraslih
No pattern of birth defects suggestive of a common etiology was seen. 
V skupni etiologiji niso opazili vzorca prirojenih napak.
Careful monitoring of the tolerance of these anticancer agents. 
Skrbno spremljanje prenašanja teh zdravil proti raku.
The clinical relevance of these preclinical data is unknown, however, the potential cardiac effects of this product in humans cannot be ruled out (see also sections 4.4 and 4.8). 
Klinični pomen teh predkliničnih podatkov ni znan, vendar kardialnih učinkov tega zdravila pri človeku ni mogoče izključiti (glejte tudi poglavji 4.4 in 4.8).
In dogs, prominent U waves on the electrocardiogram have been observed associated with prolonged PR interval and bradycardia. 
Pri psih so na elektrokardiogramu opažali izrazite zobce U v povezavi s podaljšanim intervalom PR in bradikardijo.
What Kaletra is and what it is used for What you need to know before you or your child takes Kaletra How to take Kaletra 
Kaj je zdravilo Kaletra in za kaj ga uporabljamo Kaj morate vedeti, preden boste vi ali vaš otrok vzeli zdravilo Kaletra Kako jemati zdravilo Kaletra
Kaletra is an antiretroviral medicine. 
Zdravilo Kaletra je protivirusno zdravilo.
Your doctor will advise on the amount of Kaletra to be taken. 
Zdravnik vam bo svetoval, koliko zdravila Kaletra morate vzeti.
The clinical significance of reduced abacavir and zidovudine concentrations is unknown. 
Klinični pomen znižane koncentracije abakavirja in zidovudina ni znan.
Oral solution The solution is light yellow to orange. 
peroralna raztopina Raztopina je svetlo rumene do oranžne barve.
• It is recommended that HIV-infected women do not breast-feed their infants because there is a possibility that the baby can be infected with HIV through your breast milk. 
- Priporočeno je, da s HIV okužene ženske ne dojijo, ker se otrok lahko z materinim mlekom okuži s HIV.
If you are taking Kaletra twice a day 
Če jemljete zdravilo Kaletra dvakrat na dan
If Kaletra is co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. 
Če je zdravilo Kaletra uporabljeno sočasno s parenteralnim midazolamom, je to potrebno izvesti v enoti za intenzivno nego (EIN) ali podobnem okolju, ki omogoča natančen kliničen nadzor in ustrezno medicinsko ukrepanje v primeru depresije dihanja in/ali dolgotrajne sedacije.
Buproprion and its active metabolite, hydroxybupropion: 
Buproprion in njegov aktivni presnovek hidroksibupropion:
Unless otherwise stated, studies detailed below have been performed with the recommended dosage of lopinavir/ritonavir (i.e. 400/100 mg twice daily). 
Če ni navedeno drugače, so bile spodaj omenjene študije opravljene s priporočenim odmerjanjem lopinavirja/ritonavirja (tj. 400/100 mg dvakrat na dan).
If the benefit is considered to outweigh the risk and Kaletra must be used, reduce the ibrutinib dose to 140 mg and monitor patient closely for toxicity. 
Če korist odtehta tveganje in je treba zdravilo Kaletra uporabiti, zmanjšajte odmerek ibrutiniba na 140 mg in pozorno spremljate bolnika za toksičnost.
This effect may be due to induction of bupropion metabolism. 
To je morda posledica indukcije presnove bupropiona.
See section 4.4 and section 4.5 for co-administration of sildenafil in patients with erectile dysfunction. 
Glejte poglavje 4.4 in poglavje 4.5 za sočasno uporabo sildenafila pri bolnikih z erektilno disfunkcijo.
Diarrhoea, nausea and vomiting may occur at the beginning of the treatment while hypertriglyceridaemia and hypercholesterolemia may occur later. 
Driska, slabost in bruhanje se lahko pojavijo v začetku zdravljenja, medtem ko se hipertrigliceridemija in hiperholesterolemija lahko pojavita kasneje.
Contents of the pack and other information What Kaletra contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Kaletra
This may result in lowered plasma concentrations and potential decrease of efficacy of co-administered medicinal products. 
To lahko zniža plazemske koncentracije in potencialno zmanjša učinkovitost sočasno uporabljenih zdravil.
AUC and Cmax ↓ ~50% 
AUC in Cmax ↓ ~50 %
Outcomes at Week 24: Study P1060 Cohort I 
Rezultati v 24. tednu: Študija P1060 Kohorta I
Paediatric dosing guidelines based on body weight* > 6 months to 18 years 
Smernice za pediatrično odmerjanje na osnovi telesne mase* > 6 mesecev do 18 let
Resistance to nelfinavir, defined as the presence of the D30N or L90M mutation in protease, was observed in 41/96 (43%) patients. 
Odpornost proti nelfinavirju, definirana kot prisotnost D30N ali L90M mutacij v proteazi, je bila opažena pri 41/96 (43 %) bolnikih.
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC (IZDELOVALCI), ODGOVOREN ZA SPROŠČANJE SERIJ
For monitoring of blood lipids and glucose, reference is made to established HIV treatment guidelines. 
Za nadzor lipidov in glukoze v krvi je treba upoštevati veljavne smernice za zdravljenje okužbe z virusom HIV.
Patients on a low potassium diet should be cautioned. 
Bolnike na dieti z malo kalija je treba na to opozoriti.
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART). 
Opisani so bili primeri osteonekroze, še zlasti pri bolnikih s splošno znanimi dejavniki tveganja, napredovalo boleznijo HIV ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART).
Particular risk of toxicity in relation to the amount of alcohol and propylene glycol contained in Kaletra oral solution 
Posebno tveganje toksičnosti glede na količino alkohola in propilenglikola v zdravilu Kaletra peroralna raztopina
Therefore, this co-administration should be avoided unless judged strictly necessary. 
Zato se je takšni sočasni uporabi treba izogniti, če ni res nujna.
Integrase inhibitor Raltegravir 
Zaviralci integraze Raltegravir
• severe or life threatening skin rashes and blisters (Stevens-Johnson syndrome and erythema multiforme). 
• hudi ali življenje-ogrožujoči izpuščaji in mehurji (Stevens-Johnsonov sindrom in multiformni eritem).
A limited increase in total lopinavir concentrations of approximately 30% has been observed which is not expected to be of clinical relevance (see section 4.2). 
Opazili so omejeno zvišanje koncentracij lopinavirja za približno 30 %, kar ni pričakovati, da bi bilo klinično pomembno (glejte poglavje 4.2).
Pharmaco-therapeutic group: antivirals for systemic use, antivirals for treatment of HIV infections, combinations, ATC code: J05AR10 
5.1 Farmakodinamične lastnosti Farmakoterapevtska skupina: protivirusne učinkovine za sistemsko uporabo, protivirusne učinkovine za zdravljenje okužb s HIV, kombinacije, oznaka ATC: J05AR10
Based on the current data available, Kaletra should not be administered once daily in paediatric patients (see section 5.1). 
Na podlagi dosedanjih podatkov, ki so na razpolago, se zdravila Kaletra ne sme odmerjati enkrat na dan pri pediatričnih bolnikih (glejte poglavje 5.1).
Concomitant use of Kaletra with rilpivirine causes an increase in the plasma concentrations of rilpivirine, but no dose adjustment is required. 
Sočasna uporaba zdravila Kaletra z rilpivirinom povzroči zvišanje plazemskih koncentracij rilpivirina, vendar prilagoditev odmerka ni potrebna.
If more convenient for patients, the Kaletra 200/50 mg tablets may also be considered alone or in combination with the Kaletra 100/25 mg tablet to achieve the recommended dose. 
Če je za bolnika bolj primerno, pride v poštev tudi uporaba tablet zdravila Kaletra 200/50 mg samih ali v kombinaciji s tabletami zdravila Kaletra 100/25 mg, da bi dosegli priporočeni odmerek.
Mutations L33F, I50V and V32I combined with I47V/A were also observed. 
Opažali so tudi mutacije L33F, I50V in V32I v kombinaciji z I47V/A.
These changes were reversible with withdrawal of the active substance and were absent in mice and dogs. 
Te spremembe so bile po odtegnitvi zdravilne učinkovine reverzibilne, pri miših in psih pa jih ni bilo.
It is advised to write the date of removal from the refrigerator on the package. 
Na ovojnino je priporočljivo zapisati datum, ko ste zdravilo vzeli iz hladilnika.
Haemophiliac patients should therefore be made aware of the possibility of increased bleeding. 
Bolnike s hemofilijo je zato treba seznaniti z možnostjo, da se zveča nagnjenost h krvavitvam.
You should see the ‘ml' marking aligned to the top of the collar of the barrel. 
Oznako z ‘ml' morate videti poravnano z vrhom obroča cevi.
Antibiotic 
Antibiotik
The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients (see sections 4.4 and 5.1). 
Izbira zdravila Kaletra za zdravljenje s HIV-1 okuženih in z zaviralci proteaz izkušenih bolnikov mora temeljiti na individualnem preizkusu odpornosti virusa in anamnezi bolnikovega zdravljenja (glejte poglavji 4.4 in 5.1).
No human data on the effect of lopinavir/ritonavir on fertility are available. 
Ni razpoložljivih podatkov o vplivu lopinavirja/ritonavirja na plodnost pri ljudeh.
Most tyrosine kinase inhibitors such as dasatinib and nilotinib, vincristine, vinblastine 
Večina zaviralcev tirozin kinaz, kot so dasatinib in nilotinib, vinkristin, vinblastin
Dose adjustment has not been evaluated in clinical practice. 
Prilagoditev odmerka ni ovrednotena v klinični praksi.
Healthcare professionals should be aware that Kaletra oral solution is highly concentrated and contains 42.4% alcohol (v/v) and 15.3% propylene glycol (w/v). 
Zdravstveni delavci morajo upoštevati, da je zdravilo Kaletra peroralna raztopina zelo koncentrirano in vsebuje 42,4 % alkohola (v/v) in 15,3 % propilenglikola (m/v).